Treatment-related AEs occurring in >5% patients or grade ≥3
| Treatment-related AE, n (%) | Cohort 08 (n=12) | Cohort 09 (n=14) | Total (N=26) | |||||||
| Grades 1–2 | Grades 3–4 | All grades | Grades 1–2 | Grades 3–4 | All grades | Grade 1 | Grade 2 | Grades 3–4 | All grades | |
| All AEs | 11 (91.7) | – | 11 (91.7) | 13 (92.9) | 1 (7.1) | 14 (100.0) | 13 (16.0) | 11 (42.3) | 1 (3.8) | 25 (96.2) |
| Fever | 8 (66.7) | – | 8 (66.7) | 11 (78.6) | – | 11 (78.6) | 11 (42.3) | 8 (30.8) | – | 19 (73.1) |
| Injection site reaction | 7 (58.3) | – | 7 (58.3) | 9 (62.3) | – | 9 (62.3) | 15 (57.7) | 1 (3.8) | – | 16 (61.5) |
| Proteinuria | 6 (50.0) | – | 6 (50.0) | – | – | – | 6 (23.1) | – | – | 6 (23.1) |
| Neutropenia | 3 (25.0) | – | 3 (25.0) | 2 (14.3) | 1 (7.1) | 3 (21.4) | 2 (7.7) | 3 (11.5) | 1 (3.8) | 6 (23.1) |
| Leukopenia | 3 (25.0) | – | 3 (25.0) | 1 (7.1) | 1 (7.1) | 2 (14.3) | 3 (11.5) | 1 (3.8) | 1 (3.8) | 5 (19.2) |
| Nausea | 3 (25.0) | – | 3 (25.0) | 1 (7.1) | – | 1 (7.1) | 4 (15.4) | – | – | 4 (15.4) |
| Peripheral edema | 2 (16.7) | – | 2 (16.7) | 2 (14.3) | – | 2 (14.3) | 4 (15.4) | – | – | 4 (15.4) |
| Vomiting | 3 (25.0) | – | 3 (25.0) | 1 (7.1) | – | 1 (7.1) | 3 (11.5) | 1 (3.8) | – | 4 (15.4) |
| Fatigue | 1 (8.3) | – | 1 (8.3) | 2 (14.3) | – | 2 (14.3) | 3 (11.5) | – | – | 3 (11.5) |
| Vitiligo | 1 (8.3) | – | 1 (8.3) | 2 (14.3) | – | 2 (14.3) | 3 (11.5) | – | – | 3 (11.5) |
| Chills | 2 (16.7) | – | 2 (16.7) | 1 (7.1) | – | 1 (7.1) | 3 (11.5) | – | – | 3 (11.5) |
| Pain in extremity | 3 (25.0) | – | 3 (25.0) | – | – | – | 3 (11.5) | – | – | 3 (11.5) |
| Rash | – | – | – | 2 (14.3) | – | 2 (14.3) | 2 (7.7) | – | – | 2 (7.7) |
AE, adverse event.